Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.
Treatment may depend on the cause. A sinus infection, also known as sinusitis or rhinosinusitis, occurs when your nasal cavities become swollen and inflamed. Fluid buildup in the sinuses can allow ...
A pimple-like bump or sore inside the nose can sometimes be due to nasal vestibulitis or nasal folliculitis. It is a bacterial infection that can develop when hair follicles become infected ...
Patrik Jonsson is an executive vice president at Eli Lilly and president of Lilly Cardiometabolic ... Like Ozempic, the new pill is designed to mimic the glucagon-like peptide 1 hormone that our ...
Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy) produced by Novo Nordisk A/S (NYSE: NVO) and tirzepatide (Mounjaro and Zepbound) produced by Eli Lilly and Co. (NYSE ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...